摘要 : Multikinase inhibitors (MKI) and mammalian target of rapamycin (mTOR) inhibitors prolong progression-free (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC) by reducing angiogenesis and tumo... 展开
作者 | Bendtsen~ Mathias Alro Fichtner Grimm~ Daniela Bauer~ Johann Wehland~ Markus Wise~ Petra Magnusson~ Nils E. Infanger~ Manfred Krueger~ Marcus |
---|---|
作者单位 | |
期刊名称 | 《Journal of Turbulence》 |
总页数 | 12 |
语种/中图分类号 | 英语 / O35 |
关键词 | metastatic renal cell carcinoma lenvatinib everolimus hypertension multikinase inhibitors mTOR inhibitor vascular endothelial growth factor |
馆藏号 | N2015110900144003 |